Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Endocrinology | Ophthalmology
Clinical Trials: Diabetic Retinopathy
A listing of clinical trials currently looking for volunteers to enroll in Diabetic Retinopathy studies. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Phoenix : Retina Consultants of Arizona
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
California
Beverly Hills : Retina-Vitreous Associates
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Loma Linda : Loma Linda University Health Care, Dept. of Ophthalmology
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Los Angeles : Jules Stein Eye Institute, Dept. of Ophthalmology, David Geffen School of Medicine at UCLA
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
Sacramento : Retinal Consultants Medical Group, Inc.
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Torrance : Retina Macula Institute
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Florida
Clearwater : Retina Vitreous Associates of Florida
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Fort Myers : Retina Consultants of Southwest Florida
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
St. Petersburg : Retina Vitreous Associates of Florida
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Winter Haven : Center for Retina and Macular Disease
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Georgia
Augusta : Southeast Retina Center, P.C.
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Indiana
Indianapolis : Thomas A. Cuilla, MD, PC at Midwest Eye Institute
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Kansas
Shawnee Mission : Retina Associates, PA
Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy
Kentucky
Lexington : Retina and Vitreous Associates of Kentucky
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Paducah : Paducah Retinal Center
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
New Hampshire
Portsmouth : Eyesight Ophthalmic Services, PA
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
New Jersey
Toms River : Retina Vitreous Center
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
North Carolina
Charlotte : Southeast Clinical Research Associates, LLC
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Charlotte : Charlotte Eye, Ear, Nose and Throat Assoc., PA
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Ohio
Beachwood : Retina Associates of Cleveland, Inc.
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Oregon
Portland : Retina Northwest, PC
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Pennsylvania
Lancaster : Family Eye Group
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Pittsburgh : Neuro Kinetics Inc.
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
South Dakota
Rapid City : Black Hills Regioinal Eye Institute
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Texas
Houston : Retinal Consultants of Houston
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Houston : Retina and Vitreous of Texas
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Lubbock : Texas Retina Associates
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
McAllen : Valley Retina Institute
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
San Antonio : Retinal Consultants of San Antonio
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
View More »
San Antonio : Retinal Consultants of San Antonio
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Finland
Lahti : PHSOTEY / Silmätautien klinikka
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
India
Kochi : Amrita
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Vizag : LVPEI
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Israel
Jerusalem : Hadassah Ein Kerem Medical Center
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Petah Tiqva : Rabin Medical Center
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Rehovot : Kaplan Medical Center
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Tel Aviv : Tel Aviv Sourasky Medical Center
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Zerifin : Assaf Harofe Medical Center
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Mexico
Mexico City : Conde De Valenciana
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Monterrey : Hidalgo
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
San Lucas : La Ceguera
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Switzerland
Zurich : Department of Ophthalmology, Triemli Hospital Zurich
A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)
United Kingdom
Ayr : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Birmingham : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Cardiff : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Colchester : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Devon : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
View More »
Dunfermline : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Hull : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Liverpool : Novartis Investigational Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
London : Moorfields Eye Hospital
Ranibizumab in Diabetic Vitrectomy
London : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Norfolk : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Rugby : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Uxbridge : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
York : Novartis Investigative Site
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
